Vaccines Market report categorizes the Global Market by Disease Indication (HPV, Pneumococcal, Influenza, Hepatitis, Rotavirus, DTP, Polio, MMR), Technology (Inactivated & Subunit, Recombinant, Live Attenuated, Toxoid, Conjugate), End User (Pediatrics, Adults), Type & Geography

1. Vaccines Market
worth 48.03 Billion
USD by 2021.
Live Attenuated, Toxoid, Conjugate, Inactivated & Subunit,
Recombinant), Disease Indication (Pneumococcal, Influenza, HPV,
Hepatitis, Rotavirus, DTP, Polio, MMR), End User (Pediatrics, Adults) &
Type.

2. The report "Vaccines Market by Technology (Live Attenuated, Toxoid, Conjugate, Inactivated & Subunit, Recombinant),
Disease Indication (Pneumococcal, Influenza, HPV, Hepatitis, Rotavirus, DTP, Polio, MMR), End User (Pediatrics, Adults)
& Type - Forecasts to 2021", report provides a detailed overview of the major drivers, restraints, challenges, opportunities, current
market trends, and strategies impacting the vaccines market along with the estimates and forecasts of the revenue and market share
analysis.
Browse 89 market data Tables and 55 Figures spread through 158 Pages and in-depth TOC on "Vaccines Market by
Technology (Live Attenuated, Toxoid, Conjugate, Inactivated & Subunit, Recombinant), Disease Indication (Pneumococcal,
Influenza, HPV, Hepatitis, Rotavirus, DTP, Polio, MMR), End User (Pediatrics, Adults) & Type - Forecasts to 2021"
http://www.marketsandmarkets.com/Market-Reports/vaccine-technologies-market-1155.html
Early buyers will receive 10% customization on reports.
The global vaccines market is expected to reach USD 48.03 Billion by 2021 from USD 32.24 Billion in 2016 at a CAGR of 8.3%
from 2016 to 2021. The major factor driving the growth of this market are high prevalence of diseases, rising government and
nongovernment funding for vaccine development, increasing investments by companies, and increasing focus on immunization
programs.
The report segments this market based on technology, type, disease indication, end-users, and regions. Among the various
technologies, the conjugate vaccines segment is expected to account for the largest share of the market. This segment is projected to
grow at the highest CAGR from 2016 to 2021. The high growth of this segment can be attributed to the increasing government
support for vaccine development and rising company investments.
Enquiry Before Buying: - http://www.marketsandmarkets.com/Enquiry_Before_Buying.asp?id=1155
On the basis of type, the vaccines market is segmented into monovalent vaccines and multivalent vaccines. The monovalent
vaccines segment is expected to account for the largest share of the global vaccines market in 2016 due to rising prevalence of
diseases and increasing government and non-government initiatives for vaccine R&D activities.
Disease indication, included in the vaccines market are pneumococcal disease, influenza, diphtheria, tetanus, and pertussis (DTP),
hepatitis, rotavirus, varicella, meningococcal disease, polio, measles, mumps, and rubella (MMR), human papilloma virus (HPV)
infection, and others. The pneumococcal disease segment is expected to account for the largest share of the global vaccines market
in 2016. High incidence of pneumococcal infections is driving the growth of this market.
End-users, included in the vaccines market are pediatrics and adults. The pediatrics segment is expected to account for the largest
share of the global vaccines market in 2016. Increasing prevalence of diseases in children and rising number of awareness programs
to promote vaccination will drive the growth of this market.
Based on regions, the global vaccines market is segmented into North America, Europe, Asia, and the Rest of the World (RoW).
North America is expected to account for the largest share of the market during the forecast period. Growth in this segment is driven
by increasing government funding for vaccine research and immunization.
Key players in the vaccines market include Astellas Pharma Inc. (Japan), CSL Limited (Australia), Emergent BioSolutions, Inc.
(U.S.), GlaxoSmithKline, plc. (U.K.), Johnson & Johnson (U.S.), MedImmune, LLC (U.S.), Merck & Co. (U.S.), Pfizer, Inc. (U.S.),
Sanofi Pasteur (France), and Serum Institute of India Pvt. Ltd. (India).
About MarketsandMarkets
MarketsandMarkets is the largest market research firm worldwide in terms of annually published premium market research reports.
Serving 1700 global fortune enterprises with more than 1200 premium studies in a year, M&M is catering to a multitude of clients
across 8 different industrial verticals. We specialize in consulting assignments and business research across high growth markets,
cutting edge technologies and newer applications. Our 850 fulltime analyst and SMEs at MarketsandMarkets are tracking global
high growth markets following the "Growth Engagement Model – GEM". The GEM aims at proactive collaboration with the clients
to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of
incremental revenues for both the company and its competitors.

3. M&M’s flagship competitive intelligence and market research platform, "RT" connects over 200,000 markets and entire value
chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets. The new included
chapters on Methodology and Benchmarking presented with high quality analytical infographics in our reports gives complete
visibility of how the numbers have been arrived and defend the accuracy of the numbers.
We at MarketsandMarkets are inspired to help our clients grow by providing apt business insight with our huge market intelligence
repository.
Contact:
Mr. Rohan
Markets and Markets
UNIT no 802, Tower no. 7, SEZ
Magarpatta city, Hadapsar
Pune, Maharashtra 411013, India
1-888-600-6441
Email: sales@marketsandmarkets.com